LBRX LB Pharmaceuticals Inc
LB Pharmaceuticals Inc (LBRX) is expected to report earnings on November 10, 2026, after the market close. The consensus earnings estimate is a loss of $1.30 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +4.0% since its last earnings release on August 11, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About LB Pharmaceuticals Inc
LB Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression and other neuropsychiatric diseases. LB Pharmaceuticals is based in NEW YORK.
Sector
Healthcare
Industry
Biotechnology